{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:43:04Z","timestamp":1790775784113,"version":"4.1.0"},"reference-count":102,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is defined as a chronic liver disease characterized by excessive fat accumulation in the liver without another obvious cause (no excessive alcohol consumption, hepatotoxic medications, toxins, viral infections, genetic hepatic diseases), therefore it is an exclusion diagnosis. The term NAFLD literally refers to non-alcohol related hepatopathy and does not adequately correlate with metabolic dysfunction and related cardiovascular risks. Therefore, researchers and scientific societies have moved towards changing the terminology. The novel nomenclature for a metabolic-associated fatty liver disease (MAFLD) has been proposed in 2020 by a group of experts to overcome the issues related to the old terminology. The diagnosis of MAFLD is based on the presence of hepatic steatosis and at least one between these three conditions: type 2 diabetes mellitus (T2DM), obesity or metabolic dysregulation. MAFLD has been shown to be an independent risk factor for cardiovascular diseases and atherosclerosis. It is better related to the main risk factors for atherosclerosis and cardiovascular diseases than NAFLD, such as dyslipidemia, T2DM and hypertension. The aim of this review is to highlight the reasons why the term NAFLD is moving to the term MAFLD, what are the conceptual basis of this choice and its clinical implications, particularly in the cardiovascular field.<\/jats:p>","DOI":"10.3390\/biomedicines11030883","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:29:16Z","timestamp":1678764556000},"page":"883","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-7790","authenticated-orcid":false,"given":"Andrea","family":"Boccatonda","sequence":"first","affiliation":[{"name":"Internal Medicine, Bentivoglio Hospital, AUSL Bologna, 40010 Bentivoglio (BO), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Andreetto","sequence":"additional","affiliation":[{"name":"Internal Medicine, IRCCS Azienda Ospedaliero-Universitaria Policlinico di Sant\u2019Orsola, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-4536","authenticated-orcid":false,"given":"Damiano","family":"D\u2019Ardes","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging Science, \u201cClinica Medica\u201d Institute, \u2018SS Annunziata\u2019 Hospital, \u201cG. d\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-5468","authenticated-orcid":false,"given":"Giulio","family":"Cocco","sequence":"additional","affiliation":[{"name":"Internistic Ultrasound Unit, SS Annunziata Hospital, \u201cG. d\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-9929","authenticated-orcid":false,"given":"Ilaria","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging Science, \u201cClinica Medica\u201d Institute, \u2018SS Annunziata\u2019 Hospital, \u201cG. d\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Vicari","sequence":"additional","affiliation":[{"name":"Internal Medicine, Bentivoglio Hospital, AUSL Bologna, 40010 Bentivoglio (BO), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosima","family":"Schiavone","sequence":"additional","affiliation":[{"name":"Internistic Ultrasound Unit, SS Annunziata Hospital, \u201cG. d\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cipollone","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging Science, \u201cClinica Medica\u201d Institute, \u2018SS Annunziata\u2019 Hospital, \u201cG. d\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-0891","authenticated-orcid":false,"given":"Maria Teresa","family":"Guagnano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging Science, \u201cClinica Medica\u201d Institute, \u2018SS Annunziata\u2019 Hospital, \u201cG. d\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3350\/cmh.2013.19.2.120","article-title":"Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease","volume":"19","author":"Kim","year":"2013","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States","volume":"19","author":"Younossi","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000084728","article-title":"Should nonalcoholic fatty liver disease be renamed?","volume":"23","author":"Loria","year":"2005","journal-title":"Dig. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12072-019-09990-z","article-title":"Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease","volume":"13","author":"Eslam","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MED.0000000000000432","article-title":"Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction","volume":"25","author":"Mathews","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12944-020-01288-6","article-title":"Association between nonalcoholic fatty liver disease and extrahepatic cancers: A systematic review and meta-analysis","volume":"19","author":"Liu","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl19069","article-title":"Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease","volume":"14","author":"Li","year":"2020","journal-title":"Gut Liver"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Colognesi, M., Gabbia, D., and De Martin, S. (2020). Depression and Cognitive Impairment\u2014Extrahepatic Manifestations of NAFLD and NASH. Biomedicines, 8.","DOI":"10.3390\/biomedicines8070229"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2019.01.029","article-title":"Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps","volume":"282","author":"Santos","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2018.06.029","article-title":"Human-based systems: Mechanistic NASH modelling just around the corner?","volume":"134","author":"Boeckmans","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Caligiuri, A., Gentilini, A., and Marra, F. (2016). Molecular Pathogenesis of NASH. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17091575"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3748\/wjg.v20.i7.1724","article-title":"Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease","volume":"20","author":"Ballestri","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","article-title":"Sinusoidal communication in liver fibrosis and regeneration","volume":"65","author":"Marrone","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-020-00411-3","article-title":"Role of liver sinusoidal endothelial cells in liver diseases","volume":"18","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pcad.2018.07.003","article-title":"An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases","volume":"61","author":"Elagizi","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: Risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/liv.14735","article-title":"The changing scenario of hepatocellular carcinoma in Italy: An update","volume":"41","author":"Garuti","year":"2021","journal-title":"Liver Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: The ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications","volume":"24","author":"Byrne","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.cgh.2020.07.030","article-title":"Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease","volume":"19","author":"Meyersohn","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3748\/wjg.v28.i11.1102","article-title":"Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship","volume":"28","author":"Boccatonda","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: Assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2019","journal-title":"Diabetologia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Mertens","year":"2006","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11892-008-0011-4","article-title":"Fatty liver, insulin resistance, and dyslipidemia","volume":"8","author":"Adiels","year":"2008","journal-title":"Curr. Diabetes Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cyto.2018.05.030","article-title":"Serum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis","volume":"111","author":"Altun","year":"2018","journal-title":"Cytokine"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bini, S., D\u2019Erasmo, L., Di Costanzo, A., Minicocci, I., Pecce, V., and Arca, M. (2021). The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020742"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Morinaga, J., Zhao, J., Endo, M., Kadomatsu, T., Miyata, K., Sugizaki, T., Okadome, Y., Tian, Z., Horiguchi, H., and Miyashita, K. (2018). Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193731"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12950-019-0211-5","article-title":"Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease","volume":"16","author":"Ho","year":"2019","journal-title":"J. Inflamm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1210\/jc.2007-0187","article-title":"Postprandial Lipemia Associates with Liver Fat Content","volume":"92","author":"Matikainen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1185\/03007995.2014.909394","article-title":"Postprandial lipemia as a cardiometabolic risk factor","volume":"30","author":"Pirillo","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1586\/17474124.2016.1110018","article-title":"The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development\u2014A potential therapeutic target?","volume":"10","author":"Dongiovanni","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1074\/jbc.M010029200","article-title":"Glucose and Insulin Function through Two Distinct Transcription Factors to Stimulate Expression of Lipogenic Enzyme Genes in Liver","volume":"276","author":"Koo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","article-title":"Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.4254\/wjh.v10.i7.474","article-title":"Associations between nonalcoholic fatty liver disease and ischemic stroke","volume":"10","author":"Alkagiet","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yang, Y.-J., Jung, M.-H., Jeong, S.-H., Hong, Y.-P., Kim, Y.I., and An, S.J. (2020). The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES). Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249568"},{"key":"ref_51","first-page":"661","article-title":"Association between cardiac conduction defect and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"33","author":"Wijarnpreecha","year":"2020","journal-title":"Ann. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review","volume":"73","author":"Stahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/liv.14600","article-title":"The association of non-alcoholic fatty liver disease and cardiac structure and function\u2013Framingham Heart Study","volume":"40","author":"Chiu","year":"2020","journal-title":"Liver Int."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tana, C., Ballestri, S., Ricci, F., Di Vincenzo, A., Ticinesi, A., Gallina, S., Giamberardino, M.A., Cipollone, F., Sutton, R., and Vettor, R. (2019). Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16173104"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41387-022-00182-7","article-title":"Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: A cross-sectional analysis","volume":"12","author":"Ismaiel","year":"2022","journal-title":"Nutr. Diabetes"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/CIRCEP.109.912055","article-title":"Pericardial fat is associated with prevalent atrial fibrillation: The Framingham Heart Study","volume":"3","author":"Thanassoulis","year":"2010","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/diacare.28.6.1463","article-title":"Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study","volume":"28","author":"Sone","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.aohep.2022.100762","article-title":"Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: A longitudinal cohort analysis","volume":"28","author":"Muthiah","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1023583","DOI":"10.3389\/fmed.2022.1023583","article-title":"Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease","volume":"9","author":"Perdomo","year":"2022","journal-title":"Front. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bessho, R., Kashiwagi, K., Ikura, A., Yamataka, K., Inaishi, J., Takaishi, H., and Kanai, T. (2022). A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269265"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","article-title":"MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups","volume":"67","author":"Kim","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Noda, T., Kamiya, K., Hamazaki, N., Nozaki, K., Ichikawa, T., Yamashita, M., Uchida, S., Maekawa, E., Terada, T., and Reed, J.L. (2022). The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. J. Clin. Med., 11.","DOI":"10.21203\/rs.3.rs-1268673\/v1"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","article-title":"Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: A matched case\u2013control study","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41574-021-00538-6","article-title":"Hepatic sexual dimorphism\u2014Implications for non-alcoholic fatty liver disease","volume":"17","author":"Lefebvre","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Mori, K., Tanaka, M., Hosaka, I., Mikami, T., Endo, K., Hanawa, N., Ohnishi, H., and Furuhashi, M. (2023). Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: Linear mixed-effects model analyses. Hypertens Res.","DOI":"10.1038\/s41440-023-01179-0"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40292-023-00558-5","article-title":"Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers","volume":"30","author":"Theofilis","year":"2023","journal-title":"High Blood Press Cardiovasc. Prev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100892","DOI":"10.1016\/j.aohep.2022.100892","article-title":"Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease","volume":"28","author":"Liu","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO (2016). Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1073\/pnas.1922344117","article-title":"Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease","volume":"117","author":"Luukkonen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.05.017","article-title":"Arterial stiffness and sedentary lifestyle: Role of oxidative stress","volume":"79","author":"Lessiani","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.2174\/1381612822666160413123806","article-title":"Oxidative Stress Modulation Through Habitual Physical Activity","volume":"22","author":"Boccatonda","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/liv.14638","article-title":"Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review","volume":"66","author":"Hashida","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Niederseer, D., Wernly, B., Aigner, E., Stickel, F., and Datz, C. (2021). NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030467"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.arr.2018.09.004","article-title":"Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis","volume":"48","author":"Simeone","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Perla, F.M., Prelati, M., Lavorato, M., Visicchio, D., and Anania, C. (2017). The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Children, 4.","DOI":"10.3390\/children4060046"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11886-019-1159-z","article-title":"New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease","volume":"21","author":"Katzmann","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: A randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"jc20162775","DOI":"10.1210\/jc.2016-2775","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study","volume":"102","author":"Petit","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"Birkenfeld","year":"2018","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41574-019-0266-7","article-title":"Bile acids in glucose metabolism and insulin signalling\u2014Mechanisms and research needs","volume":"15","author":"Ahmad","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"481","DOI":"10.21037\/hbsn-21-569","article-title":"Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?\u2014The results of the Pan-PPAR Lanifibranor trial","volume":"11","author":"Gastaldelli","year":"2022","journal-title":"HepatoBiliary Surg. Nutr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study","volume":"98","author":"Pierre","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis","volume":"19","author":"Siddiqui","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s12328-021-01491-7","article-title":"Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"14","author":"Malik","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","article-title":"A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis","volume":"25","author":"Jan","year":"2015","journal-title":"Obes. Surg."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.14309\/ajg.0000000000000911","article-title":"Improving Outcomes of Bariatric Surgery in Patients With Cirrhosis in the United States: A Nationwide Assessment","volume":"115","author":"Are","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: Bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2022.08.011","article-title":"Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification","volume":"357","author":"Baratta","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/3\/883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:54:00Z","timestamp":1760122440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/3\/883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":102,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["biomedicines11030883"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11030883","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]}}}